Liquid Biopsy

Digital PCR Cancer Mutation Screening Kits

Detection of multiple cancer mutation sites in a single well.

Description

Cancer is a genetic disease with uncontrolled growth of abnormal cells. Some types of cancer are frequently associated with specific genetic mutations. Those mutations provide the biomarkers that allow more specific cancer treatments, known as targeted therapy. Targeted therapy is a newer type of cancer treatment that offers patients the opportunity to use a drug that has a greater effect on cancerous tissue, reducing many of the side effects associated with standard therapy. Therefore, it is a critical step towards targeted therapy by identifying the cancer mutations with a precise and sensitive method.

Atila Biosystems provides various Digita PCR Multiplex Cancer Mutation Screening Kits, including EGFR, KRAS, BRAF, NRAS, HER2, TP53, C-KIT, APC, ROS1, ALK and RER/MET, as well as lung cancer panel. They are capable of identifying multiple mutation sites in a single well in a rapid and cost-effective manner.

EGFR Digital PCR Multiplex Mutation Screening Kit identifies possible 63 mutation sites in a single well in a rapid and cost-effective manner, including G719X, Ex19Del, S768I, Ex20Ins, T790M, L858R and L861Q mutation groups. The targets are determined by unlabeled multiplex primers and fluorescent labeled probes.

Special Features

  • Superior performance: allows quantification and screening for multiple EGFR mutations in a single well
  • High sensitivity: provides sensitive and precise detection down to 0.2% in a single well
  • Simple workflow: allows screening of multiple samples in a rapid and cost-effective manner
KRAS activating mutations are associated to approximately 15~25% of patients with lung cancer and 20~50% of patients with colorectal cancer. KRAS Digital PCR Multiplex Mutation Screening Kit identifies possible 61 mutation sites in a single well in a rapid and cost-effective manner including KRAS exon 2, 3, and 4 mutation groups. The targets are determined by unlabeled multiplex primers and fluorescent labeled probes.

Special Features

  • Superior performance: allows quantification and screening for multiple KRAS mutations in a single well
  • High sensitivity: provides sensitive and precise detection down to 0.2% in a single well
  • Simple workflow: allows screening of multiple samples in a rapid and cost-effective manner
NRAS activating mutations are associated with approximately 15~25% of patients with lung cancer and 20~50% of patients with colorectal cancer. NRAS Digital PCR Multiplex Mutation Screening Kit identifies possible 36 mutation sites in a single well in a rapid and cost-effective manner including NRAS exon 2, 3, and 4 mutation groups. The targets are determined by unlabeled multiplex primers and fluorescent labeled probes.
 

Special Features

  • Superior performance: allows quantification and screening for multiple NRAS mutations in a single well
  • High sensitivity: provides sensitive and precise detection down to 0.2% in a single well
  • Simple workflow: allows screening of multiple samples in a rapid and cost-effective manner
The p53 gene contains homozygous mutations in about 50~60% of human cancers. TP53 Digital PCR Multiplex Mutation Screening Kit identifies possible 290 mutation sites in a single well in a rapid and cost-effective manner. The targets are determined by unlabeled multiplex primers and fluorescent labeled probes.
 

Special Features

  • Superior performance: allows quantification and screening for multiple TP53 mutations in a single well
  • High sensitivity: provides sensitive and precise detection down to 0.2% in a single well
  • Simple workflow: allows screening of multiple samples in a rapid and cost-effective manner
The human epidermal growth factor receptor 2 (HER2) overexpression/amplification is associated with poor survival in breast cancer patients. HER2 Digital PCR Multiplex Mutation Screening Kit identifies possible 18 mutation sites in a single well in a rapid and cost-effective manner. The targets are determined by unlabeled multiplex primers and fluorescent labeled probes.
 

Special Features

  • Superior performance: allows quantification and screening for multiple HER2 mutations in a single well
  • High sensitivity: provides sensitive and precise detection down to 0.2% in a single well
  • Simple workflow: allows screening of multiple samples in a rapid and cost-effective manner

Mutations in the APC gene can be detected in many colorectal cancers, and these mutations are likely to be the initiating events in tumorigenesis. APC Digital PCR Multiplex Mutation Screening Kit identifies possible 38 mutation sites in a single well in a rapid and cost-effective manner. The targets are determined by unlabeled multiplex primers and fluorescent labeled probes.

Special Features

  • Superior performance: allows quantification and screening for multiple APC mutations in a single well
  • High sensitivity: provides sensitive and precise detection down to 0.2% in a single well
  • Simple workflow: allows screening of multiple samples in a rapid and cost-effective manner

PIK3CA has been reported to be mutated frequently in human cancer, particularly in common cancer types such as breast, colorectal, endometrial and prostate. PIK3CA Digital PCR Multiplex Mutation Screening Kit identifies possible 39 mutation sites in a single well in a rapid and cost-effective manner. The targets are determined by unlabeled multiplex primers and fluorescent labeled probes.

Special Features

  • Superior performance: allows quantification and screening for multiple PIK3CA mutations in a single well
  • High sensitivity: provides sensitive and precise detection down to 0.2% in a single well
  • Simple workflow: allows screening of multiple samples in a rapid and cost-effective manner

ROS1 G2032R and D2033N mutations in CD74–ROS1 conferred crizotinib resistance in patients. ROS1 Digital PCR Multiplex Mutation Screening Kit identifies possible 11 mutation sites in a single well in a rapid and cost-effective manner. The targets are determined by unlabeled multiplex primers and fluorescent labeled probes.

Special Features

  • Superior performance: allows quantification and screening for multiple ROS1 mutations in a single well
  • High sensitivity: provides sensitive and precise detection down to 0.2% in a single well
  • Simple workflow: allows screening of multiple samples in a rapid and cost-effective manner

BRAF gene mutation associated with human cancers have been identified. The frequency of BRAF mutations varies widely in human cancers, from more than 80% in melanomas and nevi, to as little as 0~18% in other tumors, such as 1~3% in lung cancers and 5% in colorectal cancer. BRAF Digital PCR Multiplex Mutation Screening Kit identifies possible 62 mutation sites in a single well in a rapid and cost-effective manner. The targets are determined by unlabeled multiplex primers and fluorescent labeled probes.

Special Features

  • Superior performance: allows quantification and screening for multiple BRAF mutations in a single well
  • High sensitivity: provides sensitive and precise detection down to 0.2% in a single well
  • Simple workflow: allows screening of multiple samples in a rapid and cost-effective manner

ALK Digital PCR Multiplex Mutation Screening Kit identifies possible 8 mutation sites in a single well in a rapid and cost-effective manner. The targets are determined by unlabeled multiplex primers and fluorescent labeled probes.

Special Features

  • Superior performance: allows quantification and screening for multiple ALK mutations in a single well
  • High sensitivity: provides sensitive and precise detection down to 0.2% in a single well
  • Simple workflow: allows screening of multiple samples in a rapid and cost-effective manner

C-KIT Digital PCR Multiplex Mutation Screening Kit identifies possible 91 mutation sites in a single well in a rapid and cost-effective manner. The targets are determined by unlabeled multiplex primers and fluorescent labeled probes.

Special Features

  • Superior performance: allows quantification and screening for multiple C-KIT mutations in a single well
  • High sensitivity: provides sensitive and precise detection down to 0.2% in a single well
  • Simple workflow: allows screening of multiple samples in a rapid and cost-effective manner

Digital PCR Lung Cancer Mutation Screening Kit is designed to identify possible 99 mutation sites in two wells in a rapid and cost-effective manner, including EGFR, KRAS, BRAF, HER2, and MET gene mutation groups. The targets are determined by unlabeled multiplex primers and fluorescent labeled probes.

Special Features

  • Superior performance: allows quantification and screening for multiple mutations highly related to lung cancer in two wells
  • High sensitivity: provides sensitive and precise detection down to 0.2% in a single well
  • Simple workflow: allows screening of multiple samples in a rapid and cost-effective manner

Technical Specs

  • Sample types: purified cfDNA
  • Reaction format: ddPCR™
  • Reaction time: ~4 hours
  • Sensitivity: as low as 0.2% mutations can be detected
  • Instruments: Bio-Rad’s QX200 Droplet Reader

 

* Order Information:

Cat. No.DescriptionSize
ACPD-EG-100EGFR Multiplex Mutation Screening Kit100 tests
ACPD-KR-100KRAS Multiplex Mutation Screening Kit100 tests
ACPD-NR-100NRAS Multiplex Mutation Screening Kit100 tests
ACPD-TP53-100TP53 Multiplex Mutation Screening Kit100 tests
ACPD-HE-100HER2 Multiplex Mutation Screening Kit100 tests
ACPD-AP-100APC Multiplex Mutation Screening Kit100 tests
ACPD-PI-100PIK3CA Multiplex Mutation Screening Kit100 tests
ACPD-RO-100ROS1 Multiplex Mutation Screening Kit100 tests
ACPD-BR-100BRAF Multiplex Mutation Screening Kit100 tests
ACPD-AL-100ALK Multiplex Mutation Screening Kit100 tests
ACPD-CK-100C-KIT Multiplex Mutation Screening Kit100 tests
ACPD-RE-100RET/MET Multiplex Mutation Screening Kit100 tests
ACPD-LN-100ddPCR™ Lung Cancer Mutation Screening Kit100 tests

*  These products are for research use only in US